Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.
Símbolo de cotizaciónANIK
Nombre de la empresaAnika Therapeutics Inc
Fecha de salida a bolsaMay 16, 1985
Director ejecutivoDr. Cheryl Renee Blanchard, Ph.D.
Número de empleados288
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 16
Dirección32 Wiggins Ave
CiudadBEDFORD
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal01730-2315
Teléfono17814579000
Sitio Webhttps://anika.com/
Símbolo de cotizaciónANIK
Fecha de salida a bolsaMay 16, 1985
Director ejecutivoDr. Cheryl Renee Blanchard, Ph.D.
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos